Obstetrics and Gynecology

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)

   Jacksonville, Fla.

   The primary purpose of this study is to determine the maximum tolerated dose (MTD) and overall safety profile of PTC596 in combination with dacarbazine for the treatment of advanced Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma (LMS).

2. A Study of ASP1948 in Subjects with Advanced Solid Tumors

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors and to characterize the pharmacokinetic profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab and determine the recommended Phase 2 dose (RP2D) of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab. This study will also evaluate the antitumor effect of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab.

3. A Study of Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples

   Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to collect vaginal and endometrial cell samples to study endometrial cancer.

4. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) alone and when combined with pembrolizumab in patients with solid tumors (RIVAL-01).

5. A Study to Evaluate Proinsulin and Glucagon Secretion in Postpartum Women with and without Gestational Diabetes

   Rochester, Minn.

   The purpose of this study is to determine the changes in tissue function that occur in the first year postpartum in women with and without gestational diabetes mellitus.

6. A Study to Evaluate Precision Pharmacogenomics in Cancer Patients

   Scottsdale/Phoenix, Ariz.

   THe purpose of this study is to examine the current and (potential) future therapeutic relevance of pharmacogenomics (PGx) testing for a cohort of cancer patients in order to improve quality of life (QOL) in patients receiving clinical care at Mayo Clinic.

7. Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients with Stage IV Melanoma and Gynecologic Cancers That Cannot Be Removed by Surgery

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab in treating patients with stage IV melanoma, gynecological cancers, or other malignancies that cannot be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab may kill more tumor cells.

8. A Study to Evaluate Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

   Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this study is to evaluate how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant. The trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.

9. A Study to Evaluate AZD1775 in Women with Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

   Rochester, Minn.

   The purpose of this study is to evaluate an investigational drug as a possible treatment for uterine cancer, AZD1775.

10. Acquisition of Fetal ECG with Intact Membranes

    Rochester, Minn.

    The purpose of this study is to determine if it is possible to record a high quality fetal ECG using signals acquired inside of the birth canal (vagina).